Raymond James Financial
MNPR icon

Raymond James Financial’s Monopar Therapeutics MNPR Stock Holding History

Raymond James Financial’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507K Buy
+5,474
New +$339K ﹤0.01% 4504
2025
Q3 		– Sell
-431
Closed -$15.4K – 6031
2025
Q2 		$15.4K Buy
+431
New +$15.7K ﹤0.01% 5713

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Raymond James Financial's MNPR Position: Q2 2026 in Review

Raymond James Financial opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 5,474 shares worth $507K. The stake represents ﹤0.01% of the portfolio and ranks #4504 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in MNPR as recently as Q2 2025.

Raymond James Financial first reported a position in MNPR in Q2 2025 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Raymond James Financial held 5,474 shares of Monopar Therapeutics worth $507K as of Q2 2026.
  • Monopar Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4504 holding.
  • Raymond James Financial first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.